News & Updates
Filter by Specialty:

Augmentation therapy with aripiprazole gets a win for difficult-to-treat depression
The addition of the antipsychotic drug aripiprazole to current antidepressant medications may help improve the symptoms of clinical depression in older adults who have not responded to standard treatments, as reported in a study.
Augmentation therapy with aripiprazole gets a win for difficult-to-treat depression
10 Mar 2023
RAS-modifying drugs reduce CVD risk in lupus patients
Use of antihypertensive agents that modify the renin-angiotensin system (RAS) helps lower the risk of cardiovascular disease (CVD) in patients with systemic lupus erythematosus (SLE), suggests a study.
RAS-modifying drugs reduce CVD risk in lupus patients
10 Mar 2023
Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?
In patients with metastatic castration-sensitive prostate cancer, triplet therapy may be ideal for fit patients with synchronous (de novo) high-volume disease while the androgen pathway inhibitor (API) doublet combinations may be preferred for those with metachronous (recurrent) low-volume disease, according to the results of a meta-analysis.
Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?
10 Mar 2023
Selgantolimod well tolerated, induces serologic changes in CHB
Treatment with the oral Toll-like receptor 8 (TLR8) agonist selgantolimod once weekly for 24 weeks is well tolerated and generally safe in patients with chronic hepatitis B (CHB) under viral suppression, according to a recent study.
Selgantolimod well tolerated, induces serologic changes in CHB
09 Mar 2023
Peg lambda cuts hospitalization, ER visits in COVID-19 outpatients
Early treatment with a single dose of pegylated recombinant IL-29 type III interferon (IFN), otherwise known as peg lambda, significantly reduced clinical events in the phase III TOGETHER study evaluating mostly vaccinated, acutely symptomatic COVID-19 outpatients.
Peg lambda cuts hospitalization, ER visits in COVID-19 outpatients
09 Mar 2023
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
In the extended follow up of the phase III CheckMate 274 trial, nivolumab continued to show benefit for patients with muscle-invasive urothelial carcinoma (MIUC; bladder, ureter, or renal pelvis) who were at high risk for recurrence following bladder resection.